---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Prevalence"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Prevalence. Topics: United States: high-risk genotype frequency among Black Americans, United States: estimated share of the Black population affected, West Africa and sub-Saharan Africa: high-risk genotype frequency, The Americas: high-risk genotype frequency in 111 populations, and 5 further topics. 9 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/prevalence"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of APOL1-mediated kidney disease

<a id="topic-2.2.1.2.2-1"></a>

### United States: high-risk genotype frequency among Black Americans

> “Based on cohort and cross-sectional studies in the United States, the estimated allelic frequency among African Americans is 20%–22% for G1 and 13%–15% for G2, with approximately 10%–15% having an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Among Black individuals in the US, the G1 allele frequency is 22% and G2 allele frequency is 13%.”
> “Approximately 13% of Black individuals in the US (more than 5 million people) have a high-risk APOL1 genotype.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “In the MVP cohort, 15,604 (12.8%) had two APOL1 HR variants, of which 582 (0.5%) also had APOL1 p.N264K.”

Source: [Hung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10631602/)

> “Allele frequencies of the G1 and G2 alleles were 22% and 13%, respectively (Table 1). Overall, 13.2% of the study sample carried two APOL1 risk alleles (G1/G1, G1/G2, or G2/G2), whereas 45.4% and 41.4% carried one (wild type [WT]/G1 or WT/G2) or zero (WT/WT) risk alleles, respectively.”

Source: [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)

<a id="topic-2.2.1.2.2-2"></a>

### United States: estimated share of the Black population affected

> “Approximately 10%–15% of the Black population has a high-risk APOL1 genotype”
> “we can estimate that up to 3% of the Black population will be affected.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.2.2-3"></a>

### West Africa and sub-Saharan Africa: high-risk genotype frequency

> “Frequencies of APOL1 high-risk genotypes are highest in West Africa, with up to 50% in Southeastern Nigeria, 37% in Central Ghana, and 25% in Southwestern Nigeria (Figure 3).”
> “Given that more than 100 million people in Sub-Saharan Africa may have 2 APOL1 high-risk alleles, the potential burden of APOL1 kidney disease in this region is catastrophically high.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “The Human Health and Heredity in Africa (H3Africa) Kidney Disease Research Network studied 8,355 participants from Ghana and Nigeria: 4,712 participants with CKD stages 2–5, 866 participants with biopsy proven glomerular diseases, and 2777 controls (eGFR ≥90 ml/min/1.73m2 without proteinuria).”
> “Overall, 43.0% and 29.7% participants carried 1 and 2 APOL1 risk variants, respectively (Table S4). The G1 haplotype was more frequent (40.7%) than the G2 haplotype (13.9%). The prevalence of APOL1 high-risk carriers was higher among persons with CKD compared to those without CKD (31.6% vs. 25.7%).”

Source: [Gbadegesin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11735277/)

> “In Africa, the APOL1 risk alleles are heavily concentrated in West Africa, and they are found at lower frequencies in eastern and southern Africa (15). For example, some groups within Nigeria or Ghana have combined risk variant allele frequencies that may exceed 50% (with high-risk genotypes of 25%), whereas individuals in Ethiopia, Sudan, and Somalia have very low probability of having two APOL1 risk variants.”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

<a id="topic-2.2.1.2.2-4"></a>

### The Americas: high-risk genotype frequency in 111 populations

> “we found elevated frequencies of the APOL1 haplotype in African-American, sub-Saharan African, and Western African populations (11 to 32%). However, we also found other populations with elevated frequencies, including Jamaican, Barbadian, Grenadian, and Brazilian from Salvador (>10 to 22%); Trinidadian, Panamanian, Honduran, Haitian, Garifunan, and Palenque (>5 to 10%); and Guyanese, Dominican, Peruvian, Belizean, and Native American (1 to 5%).”

Source: [Nadkarni et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6482949/)

<a id="topic-2.2.1.2.2-5"></a>

### Europe: high-risk genotype in unexplained kidney failure in the UK 100,000 Genomes Project

> “The study recruited 218 patients with uKF onset before age 50 years from the United Kingdom's 100,000 Genomes Project.”
> “Among individuals with recent African ancestry, high-risk APOL1 genotypes were significantly more common in those with uKF (52% vs 8.4% in those without uKF; P < 0.001).”

Source: [Sadeghi-Alavijeh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40967557/)

> “Key areas of need include prevalence data for Black populations in the Caribbean, Brazil, the United Kingdom, Belgium, France, Sub-Saharan Africa, and any populations originating after dislocation by the diaspora (Table 1).”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.2.2-6"></a>

### High-risk genotype among Black patients with nondiabetic CKD, FSGS, and hypertension-attributed ESKD

> “The high-risk genotypes are found in approximately 16%–23% of Black people with nondiabetic CKD”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “40%–60% of those with primary FSGS have 2 APOL1 risk alleles.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “A high-risk APOL1 genotype is present in about 75% of Black patients with FSGS (1,33).”
> “Similarly, approximately 50% of Black patients with hypertension-attributable ESKD have a high-risk APOL1 genotype (1).”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

<a id="topic-2.2.1.2.2-7"></a>

### High-risk genotype among people referred for APOL1 genotyping or kidney genetic testing

> “Our genotyping study is enrolling up to 4000 participants of recent African ancestry with FSGS or nondiabetic kidney disease and UPCR≥0.5g/g.”
> “The genotyping study interim analysis included 2866 participants of whom 674(23.5%) have 2 APOL1 variants; 36 of these participants enrolled in the completed Ph2 portion of AMPLITUDE.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

> “Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes.”
> “Considering APOL1 genotypes, 25.6% of patients in the genetic African ancestry cluster had high-risk APOL1 genotypes (n = 944), 39.5% were single risk allele carriers (n = 1453), and 34.8% had G0/G0 (n = 1281; Table 2 and Supplementary Figure S3).”

Source: [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)

<a id="topic-2.2.1.2.2-8"></a>

### United States, 2008 to 2018: prevalence of FSGS-attributed kidney failure in the US Renal Data System

> “The prevalence of FSGS-attributed kidney failure steadily increased over time from 76.5 per million US persons in 2008 to 96.0 per million in 2018 (Fig 2A)”

Source: [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)

<a id="topic-2.2.1.2.2-9"></a>

### Company estimates: Vertex Pharmaceuticals statements of the affected population in the United States and Europe, 2024 to 2026

> “Approximately 100,000 people in the U.S. and Europe have two APOL1 genetic variants and proteinuric kidney disease.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “Vertex plans to initiate AMPLIFIED, a Phase 2b open-label study of inaxaplin in patients with AMKD and diabetes or other co-morbidities currently not eligible for the AMPLITUDE Phase 2/3 pivotal trial, expanding the estimated potentially eligible population from 150,000 to 250,000 patients.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

> “AMKD affects an estimated patient population of approximately 250,000 in the U.S. and Europe, including AMKD patients with comorbidities.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

> “AMKD occurs in people with African ancestry, with an estimated patient population of approximately 150,000 people in the U.S. and Europe.”
> “In addition, we estimate that there are approximately 100,000 people with AMKD with comorbidities, such as type 2 diabetes, in the U.S. and Europe”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “AMKD affects approximately 150,000 people in the U.S. and Europe.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
